The mammalian cholinesterase neurotransmitters acetylcholinesterase (AChE) and butyryl choline (BuChE) and their inhibitors represent the most promising strategy for potential treatment of Alzheimer’s disease since the accumulation of β-amyloid plaques is controlled by both enzymes. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.